Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.
Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O. Laheurte C, et al. Among authors: boullerot l. Br J Cancer. 2019 Aug;121(5):405-416. doi: 10.1038/s41416-019-0531-5. Epub 2019 Jul 30. Br J Cancer. 2019. PMID: 31358938 Free PMC article.
Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O. Nardin C, et al. Among authors: boullerot l. J Invest Dermatol. 2022 Feb;142(2):435-444. doi: 10.1016/j.jid.2021.07.160. Epub 2021 Aug 2. J Invest Dermatol. 2022. PMID: 34352265 Free article.
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O. Beziaud L, et al. Among authors: boullerot l. Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17. Cancer Res. 2016. PMID: 27197194
Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.
Beziaud L, Boullerot L, Tran T, Mansi L, Marie-Joseph EL, Ravel P, Johannes L, Bayry J, Tartour E, Adotévi O. Beziaud L, et al. Among authors: boullerot l. Int J Cancer. 2018 Dec 1;143(11):3008-3018. doi: 10.1002/ijc.31842. Epub 2018 Oct 1. Int J Cancer. 2018. PMID: 30183073
Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.
Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O. Picard E, et al. Among authors: boullerot l. Oncoimmunology. 2018 Oct 19;8(2):e1527498. doi: 10.1080/2162402X.2018.1527498. eCollection 2019. Oncoimmunology. 2018. PMID: 30713781 Free PMC article.
Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O. Laheurte C, et al. Among authors: boullerot l. Int J Cancer. 2020 Aug 15;147(4):1199-1205. doi: 10.1002/ijc.32803. Epub 2019 Dec 11. Int J Cancer. 2020. PMID: 31749145
Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma.
Laheurte C, Seffar E, Gravelin E, Lecuelle J, Renaudin A, Boullerot L, Malfroy M, Marguier A, Lecoester B, Gaugler B, Saas P, Truntzer C, Ghiringhelli F, Adotevi O. Laheurte C, et al. Among authors: boullerot l. Cancer Immunol Immunother. 2023 Mar;72(3):579-589. doi: 10.1007/s00262-022-03271-9. Epub 2022 Aug 21. Cancer Immunol Immunother. 2023. PMID: 35989364 Free PMC article.
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V. Adotévi O, et al. Among authors: boullerot l. J Clin Oncol. 2023 Jan 10;41(2):373-384. doi: 10.1200/JCO.22.00096. Epub 2022 Sep 7. J Clin Oncol. 2023. PMID: 36070539 Clinical Trial.
Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O. Lauret Marie Joseph E, et al. Among authors: boullerot l. J Immunother Cancer. 2021 Jul;9(7):e002256. doi: 10.1136/jitc-2020-002256. J Immunother Cancer. 2021. PMID: 34230108 Free PMC article.
18 results